Stockscreener 앱 받기
28.31
1.91%
-0.55
시간 외 거래:
28.13
-0.18
-0.64%
전일 마감가:
$28.86
열려 있는:
$29.09
하루 거래량:
1.33M
Relative Volume:
0.50
시가총액:
$1.54B
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-34.11
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-4.65%
1개월 성능:
+345.13%
6개월 성능:
+182.53%
1년 성능:
+89.24%
1일 변동 폭
$27.51
$29.36
1주일 범위
$27.51
$30.71
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
28.31 | 1.57B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5%Here's What Happened - MarketBeat
HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Analyst Downgrade: How interest rate cuts could boost Capricor Therapeutics Inc stockWeekly Stock Analysis & Daily Profit Focused Stock Screening - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Trend Review: Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Buyback Activity & Safe Investment Capital Preservation Plans - moha.gov.vn
HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4% - MarketBeat
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
Top Medical Stocks To ResearchDecember 3rd - MarketBeat
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal - Sahm
Capricor Therapeutics launches proposed public offering of common stock - MSN
Earnings Risk: Is ARK Autonomous Technology & Robotics stock cheap by valuation metricsMarket Trend Summary & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Top Decliners & Low Risk High Win Rate Stock Picks - Улправда
How Capricor Therapeutics Inc. (4LN2) stock trades pre earningsQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Does Capricor Therapeutics Inc. stock trade at a discount to peers2025 Analyst Calls & Advanced Technical Signal Analysis - ulpravda.ru
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.8%What's Next? - MarketBeat
Capricor Therapeutics (STU:4LN2) EV-to-OCF : -21.03 (As of Dec. 19, 2025) - GuruFocus
Capricor Therapeutics (STU:4LN2) EV-to-FCF : -18.80 (As of Dec. 19, 2025) - GuruFocus
Can Capricor Therapeutics Inc. stock reach $100 price target2025 Pullback Review & Weekly Sector Rotation Insights - ulpravda.ru
Why Capricor Therapeutics Inc. (4LN2) stock is a strong analyst pick2025 Bull vs Bear & Low Drawdown Investment Ideas - DonanımHaber
CAPR stock price: Why is Capricor Therapeutics stock surging over 293% today? - MSN
Can Capricor Therapeutics Inc. (4LN2) stock double in coming years2025 Earnings Surprises & Detailed Earnings Play Alerts - Улправда
How Capricor Therapeutics Inc. stock reacts to global recession fears2025 Risk Factors & Weekly Stock Breakout Alerts - Улправда
How Capricor Therapeutics Inc. (4LN2) stock benefits from digital adoptionRecession Risk & Target Return Focused Stock Picks - Улправда
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory - Insider Monkey
Is Capricor Therapeutics Inc. stock attractive for long term wealth building2025 Price Targets & Smart Investment Allocation Tips - Улправда
Transcript : Capricor Therapeutics, Inc.Special Call - marketscreener.com
Piper Sandler reiterates Capricor stock rating, names it 2026 top pick - Investing.com UK
PPMD to host webinar on Capricor’s DMD therapy trial results By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Community Webinar on Positive HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy - The Manila Times
Capricor Therapeutics and Parent Project Muscular Dystrophy - GlobeNewswire
CAPR: B. Riley Securities Raises Target Price to $50, Maintains Buy Rating | CAPR Stock News - GuruFocus
B. Riley Adjusts Price Target on Capricor Therapeutics to $50 From $21, Maintains Buy Rating - marketscreener.com
Understanding the Setup: (CAPR) and Scalable Risk - news.stocktradersdaily.com
Capricor Therapeutics (CAPR): Reassessing Valuation After Positive Phase 3 HOPE-3 Results for Deramiocel - Sahm
How Investors May Respond To Capricor Therapeutics (CAPR) Phase 3 HOPE-3 Success And $150 Million Equity Raise - Sahm
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sidley Represents Capricor Therapeutics in US$172.5 Million Common Stock Offering - Sidley Austin
Capricor: A Detailed Examination Of Hope-3 (NASDAQ:CAPR) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on CAPR, Raises Price Target | CAPR Stock News - GuruFocus
What Does the Market Think About Capricor Therapeutics Inc? - Benzinga
Piper Sandler raises Capricor Therapeutics stock price target to $45 on trial success - Investing.com
Biotech Stocks To Add to Your WatchlistDecember 5th - MarketBeat
A strong week for data readouts: Clinical Report - BioCentury
Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial - Indian Pharma Post
Kennedy Capital Management LLC Reduces Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Oppenheimer Maintains Capricor Therapeutics (CAPR) Outperform Recommendation - Nasdaq
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):